Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Sep 28;28(5):3804-3811.
doi: 10.3390/curroncol28050324.

Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)

Isabelle Martel-Lafay  1 , Isabelle Monnet  2 , Audrey Lardy-Cleaud  3 , Serge Danhier  4 , Naji Salem  5 , Olivier Gallocher  6 , Pierre Fournel  7 , Christos Chouaid  8 , Olivier Bylicki  9 , The Gfpc-Investigators
Affiliations
Multicenter Study

Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)

Isabelle Martel-Lafay et al. Curr Oncol. .

Abstract

Concomitant radiochemotherapy (RTCT) is the standard treatment for unresectable stage III non-small cell lung cancer (NSCLC). However, in patients with a peripheral primary tumor, the irradiated volume may include a large portion of normal lung and RT-CT is not possible. This multicenter phase II trial in unresectable stage III NSCLC with peripheral primary tumor evaluated the feasibility of stereotactic body radiation therapy (SBRT) in peripheral tumor after concomitant radio-chemotherapy (RT-CT). Nineteen patients were included and analyzed (median age, 60.9 years; male, 78%; adenocarcinoma, 74%; median size of peripheral primary tumor, 19 mm). At 6 months, the disease control rate was 79% (15/19). SBRT toxicity was generally mild with one (5%) patient having grade 3 lung toxicity. Recruitment for this study was stopped prior to completion, firstly due to the approval of adjuvant durvalumab after RT-CT, which was not anticipated in the design, and secondly due to the small number of stage III NSCLC patients with a peripheral tumor that was accessible to SBRT. Nevertheless, the combination of RT-CT and SBRT appeared to be feasible and safe.

Keywords: concomitant radiochemotherapy; stereotactic body radiation therapy; unresectable stage III NSCLC.

PubMed Disclaimer

Conflict of interest statement

Chouaid, C. reports grants, personal fees, and non-financial support from AstraZeneca, Boehringer Ingelheim, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, and Amgen, outside the submitted work. The other authors have nothing to disclose.

Figures

Figure 1
Figure 1
Study design.
See this image and copyright information in PMC

References

    1. World Health Organization Cancer Fact Sheet No. 297. 2017. [(accessed on 28 September 2021)]. Available online: http://www.who.int/mediacentre/factsheets/fs297/en/
    1. Yang P., Allen M.S., Aubry M.C., Wampfler J.A., Marks R.S., Edell E.S., Thibodeau S., Adjei A.A., Jett J., Deschamps C. Clinical features of 5,628 primary lung cancer patients: Experience at Mayo Clinic from 1997 to 2003. Chest. 2005;128:452–462. doi: 10.1378/chest.128.1.452. - DOI - PubMed
    1. Goya T., Asamura H., Yoshimura H., Kato H., Shimokata K., Tsuchiya R., Sohara Y., Miya T., Miyaoka E., The Japanese Joint Committee of Lung Cancer Registry Prognosis of 6644 resected non-small cell lung cancers in Japan: A Japanese lung cancer registry study. Lung Cancer. 2005;50:227–234. doi: 10.1016/j.lungcan.2005.05.021. - DOI - PubMed
    1. Eberhardt W.E., De Ruysscher D., Weder W., Le Pechoux C., De Leyn P., Hoffmann H., Westeel V., Stahel R., Felip E., Peters S., et al. 2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer. Ann. Oncol. 2015;26:1573–1588. doi: 10.1093/annonc/mdv187. - DOI - PubMed
    1. Vokes E.E., Herndon J.E., 2nd, Crawford J., Leopold K.A., Perry M.C., Miller A.A., Green M.R. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and leukemia group B study 9431. J. Clin. Oncol. 2002;20:4191–4198. doi: 10.1200/JCO.2002.03.054. - DOI - PubMed

Publication types